The Co-Founder & CEO of Zurich based Molecular Partners describes their DARPin technology platform and how it is being put to use

blonca9
Sep 23, 2024
1 min read

Patrick Amstutz discusses the properties of DARPins that make them ideal building blocks of multispecifics and use cases such as immuno oncology and radiotherapies.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

The Co-Founder & CEO of Zurich based Molecular Partners describes their DARPin technology platform and how it is being put to use

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight